B of A Securities Downgrades Ascendis Pharma to Neutral, Raises Price Target to $169
B of A Securities analyst Tazeen Ahmad downgrades Ascendis Pharma (NASDAQ:ASND) from Buy to Neutral and raises the price target from $164 to $169.
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
Ascendis Pharma A/S Announces Presentations For TransCon PTH And TransCon CNP At American Society For Bone & Mineral Research 2021 Annual Meeting
Ascendis Pharma A/S (NASDAQ:ASND), a biopharmaceutical company using its innovative TransCon technologies to potentially create new treatments to make a meaningful difference in patients' lives, today announced
Pfizer’s Growth Hormone Candidate FDA Review Pushed By 3 Months
Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag.
The Daily Biotech Pulse: Restricted Authorization For Pfizer’s COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 22)
Ascendis Pharma Highlights Mean Bone MIneral Density Data From Phase 2 PaTH Forward Trial Showing Continued Normalization, Stabilization Of BMD Z-scores Between 26-58 Weeks
– Data from subjects with available dual energy x-ray absorptiometry (DXA) scans demonstrated stabilization of BMD, in alignment with observed bone turnover markers previously reported –
COPENHAGEN, Denmark,
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining.
The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck’s Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc.